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Purpose: The aim of our study was to prospectively evaluate the distribution of gamma-delta (γδ)1 and γδ2 T cells and their phe-
notypes in peripheral blood and prostate samples of patients diagnosed with or without prostate cancer (PCa) at prostate biopsy.
Materials and Methods: A consecutive series of 43 outpatients underwent trans-rectal echo-guided prostate biopsy for sus-
pected PCa. Flow cytometry analysis was used to identify and characterize the γδ T cells populations in peripheral blood and tissue 
samples. Patients were stratified according to the presence or not of PCa, and its International Society of Urological Pathology (ISUP) 
grade (1 vs. ≥2).
Results: The distribution of γδ T cells in peripheral blood and prostate tissue showed wide variability and non-significant differenc-
es. A slightly higher percentage of δ2 T cells and a slightly lower percentage of δ1 T cells were found in peripheral blood of cancer 
patients. A non-significantly higher percentage of both Vδ1 and Vδ2 was expressed in cancer tissues, but a trend for lower distri-
bution of δ1 and δ2 T cells was observed in ISUP grade ≥2. The “central memory” and “effector memory” were the most expressed 
T cells phenotype in peripheral blood and tissue samples. However no substantial differences in T cells subtypes distribution be-
tween cancer and healthy tissue were observed. 
Conclusions: No substantially different percentages of γδ T cells were found in peripheral blood and biopsy samples of healthy 
and PCa patients. However a non-significant trend for lower infiltrate in higher ISUP grade cancer tissue was observed, suggesting 
a possible role for the immunosurveillance of PCa. 
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INTRODUCTION
Prostate cancer (PCa) is the most common malignant 
neoplasm in male patients. PCa is a heterogeneous tumor 
with potentially long natural and clinical history, reflected 
in its common finding during autopsies carried out for other 
causes of death. In fact, many PCa are not expected to have 
clinically significant progression [1,2].
There is good evidence that cancer can naturally be 
controlled by the immune system. Mononuclear cells often 
infiltrate tumoral tissues and their presence were found to 
improve prognosis in patients with several tumors [3].
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Gamma-delta (γδ) T lymphocytes are effector cells that 
may play a critical role in cancer immunosurveillance and 
recent clinical trials support their use as immunotherapic 
agents, either via the adoptive transfer of ex vivo expan ded 
γδ T cells or following the activation of γδ T cells in vivo 
by compounds such as phosphoantigens or amino bisphos-
phonates [4].
Three main populations of γδ T cells are recognizable on 
the basis of δ chain expression, phenotypic and functional 
parameters. In fact the functional responses of γδ T cells can 
be stratified by the V region of the γδ T cell receptor (TCR). 
The γδ T cells expressing the Vδ1 TCR chain are mostly 
found in epithelial and mucosal tissues, contrasting tissutal 
damage, infection or transformation. Conversely, the γδ T 
cells expressing the Vδ2 TCR chain are the most common 
circulating γδ T lymphocytes [5], and can also act as antigen-
presenting cells [6,7], activating CD4+ T cells. Finally the Vδ3 
T cells, represent only the 0.2% of the circulating T cells [8].
Vδ1 T cells primarily reside within epithelial tissues 
(therefore also in the prostate) as f irst line agents of 
immunosurveillance, binding major histocompatibility 
complex (MHC) Class I-related ligands [9], that may act as 
tumor associated antigens. On the contrary more than the 
90% of the circulating γδ T cells express the Vδ2 receptor 
[10]. The Vγ9Vδ2 displays a broad reactivity against stress-
mediated metabolites produced by both microbial agents and 
tumors. 
Moreover, γδ T lymphocytes can be categorized for their 
different surface marker expression and effector functions 
as naive (Tnaive), central memory (Tcm), effector memory 
(Tem) and terminally differentiated (Temra) cells [11]. The γδ 
T cells development is not always completed in the thymus, 
as many of them migrate to the peripheral tissues from 
the bone marrow with immediate effector function [12]. 
While Tnaive and Tcm cells home to lymph nodes without 
immediate effector functions, Tem and Temra cells instead 
migrate to inflammation sites, displaying immediate effector 
functions [11].
Considering PCa as a model for the antitumor properties 
of local Vδ1 T and migrated Vδ2 T cells, the aim of this 
study was to prospectively evaluate the frequency, the 
phenotype and the effector function of γδ1 and γδ2 T cells 
in prostate biopsy specimens and peripheral blood samples 
according to the diagnosis of PCa (vs. healthy patients) and 
its International Society of  Urological Pathology (ISUP) 
grade.
MATERIALS AND METHODS
A consecutive series of 43 outpatients who underwent 
trans-rectal echo-guided prostate biopsy for suspicious PCa 
were enrolled. A standard 12 core sextant biopsy of  the 
peripheral zone was performed using a 16 G needle. The 
aim of the study was to assess the effect of the presence of 
PCa and its ISUP grade on the distribution of γδ T cells in 
prostate biopsy specimens and peripheral blood samples. For 
the aim of the study two additional cores (one left and one 
right) from the marginal zone of the prostate gland and a 
peripheral blood sample were taken from each patient. A 
written informed consent to participate was obtained from 
all the patients involved. According to Italian rules (art. 13, 
DLgs n. 196/03), this study did not require authorisation by 
the local ethical committee [13]. 
1. Isolation and FACS analysis of tumor-infiltrat-
ing lymphocytes and peripheral blood mono-
nuclear cells
For tumor-infiltrating lymphocytes (TILs) analysis, the 
sample tissue of the two additional cores was obtained fresh 
and immediately transported to the laboratory in ste rile 
saline solution for processing. Tissue was first minced into 
small pieces and digested with collagenase type IV, hyalu-
ronidase and DNAase (Sigma, St. Louis, MO, USA) for 
one hour at 37ºC. After digestion, the cells extracted were 
washed twice in RPMI 1640 medium.
Whole blood samples obtained from the same patients 
have been used for the comparative analysis between 
immunological status in peripheral blood and in the tumor 
or healthy tissue. The peripheral blood mononuclear cells 
(PBMCs) were separated from whole blood by density 
gradient centrifugation using Ficoll-Hypaque (Pharmacia 
Biotech, Uppsala, Sweden). Cells viability was checked by 
Trypan blue assay at microscopy.
TILs and PBMCs were stained with the same mono-
clonal antibodies (mAbs), acquired and analyzed by flow 
cytometry on FACSCalibur and FACS CANTO II. The 
entire γδ T cell population was characterized using anti-CD3 
peridinin chlorophyll protein (PerCp)-, anti-Vδ1 fluorescein 
isothiocyanate (FITC)-, anti-Vδ2 phycoerythrin (PE)-, anti-
CD27 allophycocyanin (APC)- and anti-CD45RA PE-Cy7-
conjugated mAbs (BD Biosciences, Mountain View, CA, 
USA). On the basis of  surface marker expression, we 
distinguished CD45RA+CD27+ Tnaive, CD45RA-CD27+ Tcm, 
CD45RA-CD27- Tem, CD45RA+CD27- Temra cells, according 
to previously published methods [11]. Considering the high 
specificity of the markers used, no unspecific autofluorescent 
93Investig Clin Urol 2019;60:91-98. www.icurology.org
γδ T cells in prostate cancer
or compensation background was assessed.
The gating strategy consisted in the progressive mea-
surement of total lymphocytes and specific cell types (Fig. 1). 
For every sample 100,000 nucleated cells were acquired and 
values were expressed as percentage of viable lymphocytes.
2. Statistical analysis
Patients were stratified according to the presence or 
not of PCa at sextant biopsy; the cancer patients were then 
substratified according to the ISUP grade (1 vs. ≥2). Healthy 
patients were considered those with normal histological 
findings or benign prostatic hyperplasia (BPH). The means 
of  continuous variables and the distribution of  nominal 
variables were compared with Student’s t-test and Pearson’s 
chi-squared test, respectively. All statistical analyses were 
performed using MedCalc v12.0 (MedCalc Software bvba, 
Ostend, Belgium) and GraphPad Prism v7.0 (GraphPad 
Software Inc., La Jolla, CA, USA). A p-value <0.05 was 
considered statistically significant.
RESULTS
Overall, 43 patients were enrolled. After prostate biopsy 
21 patients were diagnosed with cancer, 18 patients without 
cancer (healthy: normal or BPH) and 4 patients had prostatic 
intraepithelial neoplasia (PIN). For the aim of the study the 
Fig. 1. Gating strategy for flow cytometric analysis of lymphocytes. SSC-A, side scatter area; FSC-A, forward scatter area; FSC-H, forward scatter height; 
APC, allophycocyanin; PerCp, peridinin chlorophyll protein; FITC, fluorescein isothiocyanate; PE, phycoerythrin.
Table 1. Overall patients’ characteristics
Variable Total Healthy Prostate cancer p-value
Number of patients 36 (100) 16 (44.4) 20 (55.6)
Age (y) 67.2±7.9 63.6±9.1 70.1±5.5 0.012
Prostate specific antigen (ng/mL) 7.7±3.9 4.5±1.4 10.3±3.3 <0.001
ISUP grade
   1 - - 13 (65.0)
   2 - - 4 (20.0)
   ≥3 - - 3 (15.0)
Values are presented as number (%) or mean±standard deviation. 
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patients with PIN were excluded. Three patients, one with 
and two without cancer were excluded because of the lack of 
data. Thus 36 patients, 20 PCa and 16 healthy patients were 
included in the analysis. Overall patients’ characteristics are 
shown in Table 1. Within cancer patients, 13 (65.0%) and 7 
(35.0%) men had ISUP grade 1 and ≥2, respectively (Table 2).
The γδ T cells analysis showed wide variability both on 
prostate biopsy and PBMC samples. Data showed a slightly 
higher percentage of δ2 T cells (2.6% vs. 2.1%) and a slightly 
lower percentage of δ1 T cells (0.5% vs. 0.7%) in peripheral 
blood of cancer patients in comparison with healthy patients, 
although not significant (Fig. 2A). Moreover the analysis 
of  the PBMC samples showed a non-significantly higher 
percentage of Tem and Temra phenotypes in PCa patients 
Table 2. Cancer patients’ characteristics stratified according ISUP grade
Variable Total ISUP grade 1 ISUP grade ≥2 p-value
Number of patients 20 (100) 13 (65.0) 7 (35.0)
Age (y) 70.1±5.5 69.4±5.5 71.4±5.5 0.439
Prostate specific antigen (ng/mL) 10.3±3.3 10.3±3.9 10.3±1.7 0.992
Positive cores 5.4±3.1 5.0±2.9 6.3±3.5 0.394
Values are presented as number (%) or mean±standard deviation.
Fig. 2. (A) Percentage of total Vδ1 and Vδ2 T cells in peripheral blood samples of healthy and prostate cancer (PCa) patients. (B) Distribution of Vδ1 and 
Vδ2 T cells subsets in peripheral blood samples of healthy and PCa patients. (C) Percentage of total Vδ1 and Vδ2 T cells in prostate biopsy samples of 
healthy and PCa patients. (D) Distribution of Vδ1 and Vδ2 T cells subsets in prostate biopsy samples of healthy and PCa patients. Light blue columns iden-
tify Vδ1 and pink columns identify Vδ2 T cells. Tnaive, naive T cells; Tcm, central memory T cells; Tem, effector memory T cells; Temra, terminally differenti-
ated T cells. Means were compared through Student t-test: p-values are reported above the corresponding columns.
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(Fig. 2B).
On the contrary, TILs analysis showed a non-significant 
trend for higher expression of both δ1 and δ2 T cells in PCa 
patients (6.1% and 8.5% vs. 5.7% and 4.3% in healthy tissues, 
respectively) (Fig. 2C).
However, δ2 T cells obtained from peripheral blood 
of cancer subjects showed a predominant Tcm phenotype 
(38.5%), while the dominant phenotype in the PCa tissue 
was the Tem phenotype (40.3%). These results, although 
not statistically significant, could suggest that the cells 
committed to effector activities at the tumor site are 
phenotypically different respect to circulating δ2 T cell. 
Nevertheless the phenotypes of δ2 T cells in healthy and 
PCa tissue were substantially similar.
Regarding the δ1 T cells, the most prevalent PBMCs 
phenotype in PCa patients was Temra (40.7%), while the 
most prevalent tissutal phenotype was Tem (38.3%; Fig. 
2B–D). On the contrary the most prevalent phenotypes in 
PBMCs of healthy subject were Tnaive and Tcm. However, 
also for the Vδ1 T cells, the distribution of the phenotypes 
in healthy and PCa tissue was substantially similar (not 
statistically significant).
The percentage of tumor-infiltrating γδ T cells according 
to ISUP grade is shown in the Fig. 3. A non-significant trend 
was found for lower percentage of infiltrating δ1 and δ2 T 
cell in more aggressive cancer (ISUP grade ≥2) in comparison 
with ISUP grade 1 (p=0.495 and 0.401, respectively). However, 
within the T cells subsets, the δ2 Tnaive were significantly 
more present in the high grade tumors (p=0.031; Fig. 3B).
DISCUSSION
In this study the circulating and tumor infiltrating γδ 
T cells were investigated in patients diagnosed with and 
without PCa at prostate biopsy. No substantially different 
percentages of γδ T cells were found in peripheral blood 
and biopsy samples of healthy and PCa patients. A non-
significant trend for higher expression of both δ1 and δ2 
T cells in cancer tissues and for lower expression in more 
aggressive cancer (ISUP grade ≥2) were found in comparison 
with healthy tissue and ISUP grade 1 cancer, respectively. 
Moreover we observed a slightly, although not significant, 
higher percentage of δ2 T cells and lower percentage of δ1 T 
cells in peripheral blood of cancer patients. 
Although the effector functions of  aß and γδ T cells 
are similar, γδ TCR binds also tumor-associated ligands in 
a MHC-independent manner [14], but the exact role of γδ T 
cells is controversial and not well understood yet. Specifically 
mediating the antigen-specific killing of  cancer cells, γδ 
T cells have been associated with improved prognosis in 
patients with different types of carcinoma, in a retrospective 
analysis by Gentles et al. [15]. On the contrary some γδ T 
cells subgroups can activate immunosuppressive pathways 
and angiogenesis, supporting cancer progression. In this case 
overriding the interferon γ mediated antitumor immune 
response, interleukin (IL)-17 is an important mediator of such 
protumor functions [9]. IL-17 expression is higher in several 
human tumors, such as ovarian, cervical cancer, breast 
cancer, hepatocellular carcinoma, esophageal cancer, gastric 
and colorectal cancer [14,16]. Interestingly, γδ T cells are rare 
and not recruited nor expanded within renal cell carcinomas 
Fig. 3. (A) Percentage of total Vδ1 and Vδ2 T cells in prostate biopsy samples of prostate cancer (PCa) patients stratified according to ISUP grade (1 vs. ≥2). (B) 
Distribution of Vδ1 and Vδ2 T cells subsets in in prostate biopsy samples of PCa patients stratified according to ISUP grade (1 vs. ≥2). Light blue columns 
identify ISUP grade 1 and pink columns identify ISUP grade ≥2. Tnaive, naive T cells; Tcm, central memory T cells; Tem, effector memory T cells; Temra, ter-
minally differentiated T cells. Means were compared through Student t-test: p-values are reported above the corresponding columns (*p<0.05).
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and do not correlate with prognostic features nor specific 
death [17]. On the other hand, intratumoral γδ T cells amount 
was reported to be positively correlated with advanced 
stages and lymph node metastasis, and thus inversely 
correlated with both relapse-free and overall survival in 
breast cancer patients [18]. It is important to note that γδ 
T cells secrete IL-10 [19] and IL-17 [20,21] regulating CD8+ T 
cell, neutrophils and monocytes recruitment and expansion, 
initiating the inflammatory response. Such functions could 
be exploited for immunotherapy; in fact promising results 
were reported in small-scale applications of Vγ9Vδ2 T cells 
to hematologic [22] and solid-tissue malignancies, including 
PCa and advanced renal cell carcinoma [23]. Moreover 
recent clinical trials support the use of γδ T lymphocytes as 
immunotherapeutic agents, either via the adoptive transfer 
of ex vivo expanded γδ T cells or following their activation 
in vivo [24].
The adult prostate contains several endogenous infla-
mmatory infiltrates consisting of a variable amount of T 
and B lymphocytes, macrophages and mast cells [3], that may 
have an important role in cancer pathogenesis (progression 
or inhibition). T lymphocytes are often induced in PCa 
patients and infiltrate the tumor. In fact CD3+ and CD4+ 
T lymphocytes infiltrates have been shown to be clustered 
around PCa islets with only few lymphocytes scattered 
within the tumor area. CD3+ lymphocytes clusters contain 
numerous CD25+ and FOXP3+ cells with regulatory function, 
inhibiting immune response against cancer cells [25]. Also 
the CD8+ T cells are recruited into the prostate; however 
they express high levels of  the inhibitory receptor PD-1, 
indicating exhaustion and inability of mounting an effective 
immune response [26]. 
Miller et al. [27] showed that CD4+CD25+ regulatory T 
cells (Treg) are increased in the tumor tissue and peripheral 
blood of early-stage PCa patients who had undergone radical 
prostatectomy compared with benign tissue from the same 
prostate and peripheral blood of normal donors, concluding 
that these cells may play a role in modulation of effector T 
cell responses against PCa.
Our study demonstrates a non-significant trend for 
higher expression of both δ1 and δ2 T cells in PCa tissue; 
the majority of  PCa-inf iltrating Vδ2 T cells showed 
Tem and Temra phenotypes, indicating cells homing to 
inf lammation sites with immediate ef fector function 
as cytokine production. Their presence in the context of 
PCa could suggest a migratory process from the blood or 
lymphoid tissues, having a role in the immunosurveillance 
of this tumor. However also the γδ T cells found in healthy 
tissues primarily showed Tem phenotype. Conversely, 
circulating Vδ2 T from the same patients primarily showed 
Tcm phenotype that identifies cells homing to secondary 
lymphoid organs, without immediate effector function. 
Accordingly Norström et al. [28] reported a greatly different 
subset composition within lymphocytes isolated from BPH 
tissue sampled after trans urethral resection compared to 
those from peripheral blood, reflecting a different role of 
the immune system in different bodily environments. In 
particular both co-inhibitory and co-stimulatory receptors 
expressing T cells were described to be more present in BPH 
tissue compared to PBMCs, suggesting chronic activation 
and possible functional exhaustion of  TILs. Moreover a 
recent study reported that the majority of T-cells infiltrating 
the prostate showed Tem phenotype and those from PCa 
tissue could be on average 20-fold higher than that obtained 
from controls (BPH and normal prostates); on the other hand 
Treg cells did not seem to be unique to the PCa setting, but 
they were frequently found in the prostate gland compared 
to peripheral blood regardless of prostate condition, again 
indicating a role in prostate homeostasis [29].
Finally it is noteworthy that in our population lower, 
although not significant, levels of infiltrating γδ T cells were 
found in more aggressive PCa (ISUP grade ≥2). Similarly, in 
a previous study reporting a higher percentage of Treg and 
T helper (Th) 17 CD4+ TILs in PCa tissue, a different T cells 
phenotype distribution was associated with PCa grade; in 
particular a preponderant Th17-mediated inflammation was 
associated with lower Gleason score [30].
If confirmed in larger studies, this could be important 
as the Gleason score is an independent prognostic factor of 
PCa and in many cases can guide the therapeutic choice 
(surveillance vs. active treatment) [1].
This small prospective study still cannot give answers on 
the potential independent prognostic value of the γδ T cells 
isolation on PCa bioptic specimens. One limitation could be 
that the TILs analyses were performed on two additional 
biopsy cores, without the certainty that the tissues sampled 
would be the same of the diagnostic ones (12 cores sextant 
biopsy). However it is known that the prostate tissue is 
highly variable and PCa is typically multifocal, unilateral 
or bilateral. According to this and the typical distribution 
of the TILs infiltrate already described in literature [25], we 
considered appropriate the analysis of the additional cores 
almost near to the positive ones. Moreover we considered as 
healthy those patients without cancer at biopsy, including 
those with normal histological findings and BPH; all the 
patients presented focal signs of inflammatory response at 
pathological examination, as usual in clinical practice.
This is the first report of  the γδ T cells isolation on 
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prostate biopsy specimen in relation to PCa diagnosis and 
ISUP grade in a cohort of subjects with homogenous clinical 
characteristic (age and prostate specific antigen values). 
Future studies should focus on the role of γδ T cells in PCa 
progression, but also in pre-malignant conditions as PIN.
CONCLUSIONS 
The study of  tumor infiltrating lymphocytes subpo-
pulation is feasible in prostate biopsy samples. No 
substantially different percentages of γδ T cells were found 
in peripheral blood and biopsy samples of healthy and PCa 
patients. However a non-significant trend for lower infiltrate 
in higher grade cancer (ISUP grade ≥2) was observed. γδ T 
cells might have a central role in this context but we are 
still far from their clinical use. In fact the exact role of 
T cells in immunosurveillance and in tumor progression, 
particularly in relation to specific cytokines production, 
needs better understanding.
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